Recent Advance in Immunosuppressive Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 32
Special Issue Editor
Special Issue Information
Dear Colleagues,
Immunosuppressive drugs inhibit the body's immune response and the proliferation and functioning of immune response cells. The beginnings of immunosuppressive therapy date back to the 1960s and 1970s. The introduction of new drugs in the 1990s allowed for the use of treatment protocols using combinations of different agents. It is worth noting that many immunosuppressive agents are still in clinical or preclinical trials. Currently, immunosuppressive drugs are mainly used in patients after the transplantation of vascularized organs and in autoimmune and chronic inflammatory diseases. However, in some patients, there is still a need to modify immunosuppressive treatment protocols due to the high toxicity of the drug. In this context, an important aspect is the selection of appropriate immunosuppressive drugs which maximize overall therapeutic efficacy, minimize various side effects, and improve the quality of life of patients. Currently, scientists and clinicians are trying to develop common features between immunosuppressive drugs with the same target, while also taking up the challenge of targeting these drugs to selected cells.
In recent years, there has been significant progress in the development and introduction of biologics and cell-based therapies designed to target basic signaling pathways. This strategy is characterized by high efficacy and represents a new approach to the control of the patient's clinical condition or prevention of disease progression. In addition, there is an emphasis on biomarkers and genetic profiling, which allows for a personalized approach to therapy while ensuring the precise and non-invasive monitoring of the patient's condition.
The present Special Issue of the International Journal of Molecular Sciences aims to gain insight into recent advances in immunosuppressive therapy in regard to the mechanisms of action, signaling pathways, therapeutic efficacy, biological treatment, cell-based therapies, biomarkers, genetic profiling, and other aspects related to immunosuppressive agents.
Dr. Marta Grabowska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunosuppressive drugs
- calcineurin inhibitors
- corticosteroids
- inhibitors of purine synthesis
- mammalian target of rapamycin inhibitors
- biological treatment
- cell-based therapies
- biomarkers
- genetic profiling
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
